BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 36993400)

  • 1.
    Nesic K; Krais JJ; Vandenberg CJ; Wang Y; Patel P; Cai KQ; Kwan T; Lieschke E; Ho GY; Barker HE; Bedo J; Casadei S; Farrell A; Radke M; Shield-Artin K; Penington JS; Geissler F; Kyran E; Zhang F; Dobrovic A; Olesen I; Kristeleit R; Oza A; Ratnayake G; Traficante N; ; DeFazio A; Bowtell DDL; Harding TC; Lin K; Swisher EM; Kondrashova O; Scott CL; Johnson N; Wakefield MJ
    medRxiv; 2023 Aug; ():. PubMed ID: 36993400
    [No Abstract]   [Full Text] [Related]  

  • 2. The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
    Wang Y; Bernhardy AJ; Cruz C; Krais JJ; Nacson J; Nicolas E; Peri S; van der Gulden H; van der Heijden I; O'Brien SW; Zhang Y; Harrell MI; Johnson SF; Candido Dos Reis FJ; Pharoah PD; Karlan B; Gourley C; Lambrechts D; Chenevix-Trench G; Olsson H; Benitez JJ; Greene MH; Gore M; Nussbaum R; Sadetzki S; Gayther SA; Kjaer SK; ; D'Andrea AD; Shapiro GI; Wiest DL; Connolly DC; Daly MB; Swisher EM; Bouwman P; Jonkers J; Balmaña J; Serra V; Johnson N
    Cancer Res; 2016 May; 76(9):2778-90. PubMed ID: 27197267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
    Pettitt SJ; Shao N; Zatreanu D; Frankum J; Bajrami I; Brough R; Krastev DB; Roumeliotis TI; Choudhary JS; Lorenz S; Rust A; de Bono JS; Yap TA; Tutt ANJ; Lord CJ
    Oncogene; 2023 Sep; 42(36):2701-2709. PubMed ID: 37491606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
    Smith LD; Leme de Calais F; Raponi M; Mellone M; Buratti E; Blaydes JP; Baralle D
    Int J Cancer; 2017 Apr; 140(7):1564-1570. PubMed ID: 27997688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanopore sequencing of full-length BRCA1 mRNA transcripts reveals co-occurrence of known exon skipping events.
    de Jong LC; Cree S; Lattimore V; Wiggins GAR; Spurdle AB; ; Miller A; Kennedy MA; Walker LC
    Breast Cancer Res; 2017 Nov; 19(1):127. PubMed ID: 29183387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene.
    Bonnet C; Krieger S; Vezain M; Rousselin A; Tournier I; Martins A; Berthet P; Chevrier A; Dugast C; Layet V; Rossi A; Lidereau R; Frébourg T; Hardouin A; Tosi M
    J Med Genet; 2008 Jul; 45(7):438-46. PubMed ID: 18424508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
    Chevalier LM; Billaud A; Fronteau S; Dauvé J; Patsouris A; Verriele V; Morel A
    Mol Diagn Ther; 2020 Apr; 24(2):233-243. PubMed ID: 32124385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of two novel BRCA1 germ-line mutations involving splice donor sites.
    Brose MS; Volpe P; Paul K; Stopfer JE; Colligon TA; Calzone KA; Weber BL
    Genet Test; 2004; 8(2):133-8. PubMed ID: 15345110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-nucleotide substitution T to A in the polypyrimidine stretch at the splice acceptor site of intron 9 causes exon 10 skipping in the
    Sasai H; Aoyama Y; Otsuka H; Abdelkreem E; Nakama M; Hori T; Ohnishi H; Turner L; Fukao T
    Mol Genet Genomic Med; 2017 Mar; 5(2):177-184. PubMed ID: 28361105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes.
    Théry JC; Krieger S; Gaildrat P; Révillion F; Buisine MP; Killian A; Duponchel C; Rousselin A; Vaur D; Peyrat JP; Berthet P; Frébourg T; Martins A; Hardouin A; Tosi M
    Eur J Hum Genet; 2011 Oct; 19(10):1052-8. PubMed ID: 21673748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
    Wang Y; Krais JJ; Bernhardy AJ; Nicolas E; Cai KQ; Harrell MI; Kim HH; George E; Swisher EM; Simpkins F; Johnson N
    J Clin Invest; 2016 Aug; 126(8):3145-57. PubMed ID: 27454289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6.
    Raponi M; Kralovicova J; Copson E; Divina P; Eccles D; Johnson P; Baralle D; Vorechovsky I
    Hum Mutat; 2011 Apr; 32(4):436-44. PubMed ID: 21309043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 15. Integrative genomic analysis of drug resistance in
    Xu Y; Gu L; Li Y; Zhao R; Jian H; Xie W; Liu L; Wu H; Ren F; Han Y; Lu S
    Front Oncol; 2022; 12():1024818. PubMed ID: 36338758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 exon 11 a model of long exon splicing regulation.
    Raponi M; Smith LD; Silipo M; Stuani C; Buratti E; Baralle D
    RNA Biol; 2014; 11(4):351-9. PubMed ID: 24658338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
    Wappenschmidt B; Becker AA; Hauke J; Weber U; Engert S; Köhler J; Kast K; Arnold N; Rhiem K; Hahnen E; Meindl A; Schmutzler RK
    PLoS One; 2012; 7(12):e50800. PubMed ID: 23239986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of a
    Hurley RM; McGehee CD; Nesic K; Correia C; Weiskittel TM; Kelly RL; Venkatachalam A; Hou X; Pathoulas NM; Meng XW; Kondrashova O; Radke MR; Schneider PA; Flatten KS; Peterson KL; Becker MA; Wong EM; Southey MS; Dobrovic A; Lin KK; Harding TC; McNeish I; Ross CA; Wagner JM; Wakefield MJ; Scott CL; Haluska P; Wahner Hendrickson AE; Karnitz LM; Swisher EM; Li H; Weroha SJ; Kaufmann SH
    NAR Cancer; 2021 Sep; 3(3):zcab028. PubMed ID: 34316715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.